Subscribe Now Subscribe Today
FOLLOW US:     Facebook     Twitter
International Journal of Pharmacology
  Year: 2005 | Volume: 1 | Issue: 1 | Page No.: 17-24
DOI: 10.3923/ijp.2005.17.24
Biologic Management of Fistulizing Crohn’s Disease
Ali Rezaie , Bardia Taghavi Bayat and Mohammad Abdollahi

Fistulas, occurring in about 20 to 40% of Crohn’s disease patients, are usually resistant to conventional therapy of CD. Biologic therapies, which have revolutionary beneficial effects on diseases with an immunologic background, are a new horizon in treating fistulizing CD. The aim of this study was to evaluate the efficacy of biologic agents used to treat fistulizing CD after a brief overview on epidemiology and pathophysiology of fistulizing CD and definition of biologic therapy. Also it focuses on the trials and adverse effects of the biologic agents proved to be effective (Infliximab and CDP571).
 [Fulltext PDF]   [References]   [Report Citation]
  •    Efficacy and Incontinence Rate of Biomaterials (Fibrin Glue and Fibrin Plug) in Comparison to Surgical Interventions in the Treatment of Perianal Fistula: A Systematic Review and Meta-analysis of Randomized, Controlled Trials
  •    New Horizons in Management of Inflammatory Bowel Disease
How to cite this article:

Ali Rezaie , Bardia Taghavi Bayat and Mohammad Abdollahi , 2005. Biologic Management of Fistulizing Crohn’s Disease. International Journal of Pharmacology, 1: 17-24.

DOI: 10.3923/ijp.2005.17.24